Ipsen Biopharmaceuticals, Inc.
650 E Kendall Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
464 articles with Ipsen Biopharmaceuticals, Inc.
It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
1/3/2019New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.
For many people France may is synonymous with wines, cheese and rich meals. But the country also has a strong biotech community that how grown significantly over the past decade, with a strong focus on developing clinical drug assets.
Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
With a patient-centric focus, Ipsen Biopharmaceuticals is on a mission to improve patients’ lives, leveraging its global reach and placing a strategic focus on external innovation.
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).
Ipsen Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
11/2/2018Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!
Ipsen Delivers Strong Sales Growth of 20.2%1 for the Third Quarter of 2018 and Confirms Full Year Guidance
Ipsen today announced sales for the third quarter of 2018.
Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress
Patients in a real-world setting experienced similar dosing patterns as seen in the pivotal Phase 3 NAPOLI-1 clinical trial
Health Canada approves XERMELOTM (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)
XERMELO is a first-in-class treatment option for patients whose refractory carcinoid syndrome diarrhea is inadequately controlled with somatostatin analogue (SSA) therapy alone2
Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress
Ipsen today announced that cabozantinib (Cabometyx®), irinotecan liposome injection (Onivyde®), lanreotide (Somatuline®) and the combination of lanreotide and telotristat (Xermelo®) are the subject of 12 presentations at the 2018 European Society for Medical Oncology (ESMO) annual congress. The meeting takes place in Munich, Germany, October 19-23, 2018.
Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced the appointment of Ed Dybka as General Manager, effective October 15.
Ipsen Presents Data on Somatuline® Depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that seven studies have been selected for poster presentations at the annual symposium of the North American Neuroendocrine Tumor Society (NANETS) taking place in Seattle, Washington, Oct. 4-6, 2018.
Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced it has joined the Biotechnology Innovation Organization (BIO), the largest association of biotechnology companies, academic institutions and biotech centers around the world, and a leader in biotech innovation for over a quarter of a century.
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)
Ipsen announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults
Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit
Health Canada Approves Ipsen's CABOMETYX Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma
CABOMETYX™ is the first and only single agent to demonstrate statistically significant clinical benefits across three key efficacy endpoints of overall survival (OS), progression free survival (PFS) and objective response rate (ORR) in a phase 3 study in previously treated patients with advanced renal cell cancer
9/5/2018Summer is coming to an end, but the job front is still sizzling. Check out the top companies who are looking for candidates like you right now!
Ipsen Delivers Strong Results for the First Half of 2018 with Sales Growth of 21.5%1 and Upgrades Its Guidance for Full Year 2018
Ipsen announced financial results for the first half of 2018.